Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Structure Therapeutics Inc. American Depositary Shares (GPCR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/20/2025: GPCR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 43.8% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.25B USD | Price to earnings Ratio - | 1Y Target Price 76.32 |
Price to earnings Ratio - | 1Y Target Price 76.32 | ||
Volume (30-day avg) 791698 | Beta -1.97 | 52 Weeks Range 13.22 - 47.48 | Updated Date 06/21/2025 |
52 Weeks Range 13.22 - 47.48 | Updated Date 06/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.58 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -17.24% | Return on Equity (TTM) -22.85% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 423280040 | Price to Sales(TTM) - |
Enterprise Value 423280040 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -13.46 | Shares Outstanding 57536800 | Shares Floating 146219869 |
Shares Outstanding 57536800 | Shares Floating 146219869 | ||
Percent Insiders 2.74 | Percent Institutions 101.14 |
Analyst Ratings
Rating 4.57 | Target Price 76.32 | Buy 6 | Strong Buy 8 |
Buy 6 | Strong Buy 8 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Structure Therapeutics Inc. American Depositary Shares
Company Overview
History and Background
Structure Therapeutics Inc. (formerly Schru00f6dinger China) was founded in 2016. It focuses on developing novel oral therapeutics for chronic diseases with significant unmet needs, using its innovative structure-based drug discovery platform.
Core Business Areas
- GPCR-targeted therapeutics: Focuses on developing oral small molecule drugs targeting G protein-coupled receptors (GPCRs) for metabolic, pulmonary, and other diseases.
- Structure-based drug discovery: Utilizes advanced computational methods to design and optimize drug candidates with improved potency, selectivity, and bioavailability.
Leadership and Structure
Raymond Stevens (Founder and CEO), alongside a leadership team with experience in drug discovery and development. The company is organized around research, development, and corporate functions.
Top Products and Market Share
Key Offerings
- GSBR-1290 (Oral GLP-1RA): GSBR-1290 is an oral small molecule GLP-1 receptor agonist being developed for type 2 diabetes and obesity. Market share data is not yet available as it is in clinical development. Competitors include Novo Nordisk (Ozempic, Rybelsus, Wegovy), Eli Lilly (Mounjaro), and other companies developing oral GLP-1 agonists.
- APEX (GPCR platform): Proprietary platform for structure-based drug discovery, enabling the design of novel GPCR-targeted therapeutics. Revenue generation is tied to successful drug development and potential licensing agreements.
Market Dynamics
Industry Overview
The pharmaceutical industry, especially the segment focused on metabolic diseases like diabetes and obesity, is experiencing significant growth due to increasing prevalence and demand for novel therapies. The GPCR-targeted drug market is also expanding.
Positioning
Structure Therapeutics is positioned as an innovator in oral small molecule GPCR-targeted therapeutics. Its competitive advantage lies in its structure-based drug discovery platform and focus on developing convenient oral alternatives to injectable biologics.
Total Addressable Market (TAM)
The total addressable market for GLP-1 receptor agonists (injectable and oral) is estimated to reach tens of billions of dollars annually. Structure Therapeutics aims to capture a significant portion of this market with its oral GLP-1RA, GSBR-1290. The overall GPCR targeted therapeutics is even larger, exceeding $100 billion.
Upturn SWOT Analysis
Strengths
- Proprietary structure-based drug discovery platform
- Focus on oral small molecule GPCR-targeted therapeutics
- Strong leadership team with expertise in drug discovery
- Promising clinical data for GSBR-1290
Weaknesses
- Clinical trial execution risk
- Limited commercialization experience
- Dependence on successful development of pipeline candidates
- Competition from established pharmaceutical companies
Opportunities
- Expanding GLP-1RA market
- Potential for licensing and partnerships
- Development of additional GPCR-targeted therapeutics
- Advancements in structure-based drug discovery technologies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established therapies
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- LLY
- NVO
- MRK
- PFE
Competitive Landscape
Structure Therapeutics competes with established pharmaceutical companies in the diabetes and obesity market. Its advantages lie in its innovative oral small molecule approach and focus on GPCR-targeted therapeutics. Disadvantages include limited resources and commercialization experience compared to larger competitors.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by successful fundraising and the advancement of its drug discovery platform and pipeline.
Future Projections: Future growth is projected to be driven by successful clinical trials, potential regulatory approvals, and commercialization of its therapies, particularly GSBR-1290.
Recent Initiatives: Recent initiatives include the advancement of GSBR-1290 into Phase 2 clinical trials and the expansion of its GPCR-targeted drug discovery platform.
Summary
Structure Therapeutics is a clinical-stage biopharmaceutical company with a promising structure-based drug discovery platform, particularly focused on oral GPCR-targeted therapeutics. The company's success hinges on the clinical development of GSBR-1290. Strong competition exists, however its innovative approach to drug design and development may offer competitive advantages. Its lack of commercial experience requires partnerships for the future.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual research and consultation with a qualified financial advisor. Market share estimates are based on available data and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Structure Therapeutics Inc. American Depositary Shares
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2023-02-03 | CEO & Director Dr. Raymond C. Stevens Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 183 | Website https://structuretx.com |
Full time employees 183 | Website https://structuretx.com | ||
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in preclinical trial to treat obesity; ANPA-0073, an oral small molecule agonist targeting the apelin, which is phase 2 ready for selective weight loss or muscle-sparing weight loss; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.